Sector Gamma AS Sells 7,153 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sector Gamma AS lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 99,000 shares of the medical research company's stock after selling 7,153 shares during the quarter. Edwards Lifesciences comprises approximately 2.5% of Sector Gamma AS's holdings, making the stock its 17th largest position. Sector Gamma AS's holdings in Edwards Lifesciences were worth $7,329,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of EW. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $555,939,000. Assenagon Asset Management S.A. raised its stake in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after buying an additional 3,506,886 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $213,844,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock valued at $243,745,000 after buying an additional 2,606,950 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Canaccord Genuity Group increased their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $79.95.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 0.1 %

EW stock traded down $0.06 during mid-day trading on Tuesday, hitting $71.29. The stock had a trading volume of 6,112,449 shares, compared to its average volume of 4,620,801. The stock has a market capitalization of $41.91 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a fifty day moving average of $71.43 and a 200 day moving average of $70.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.